Ramadan Mohammad Said, Gallo Raffaella, Patauner Fabian, Bertolino Lorenzo, Durante-Mangoni Emanuele
Department of Precision Medicine, University of Campania 'L. Vanvitelli' Napoli, Italy and Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, 80131 Napoli, Italy.
Rev Cardiovasc Med. 2022 Aug 5;23(8):277. doi: 10.31083/j.rcm2308277. eCollection 2022 Aug.
Novel cardiac devices, including the MitraClip system, occluder devices, leadless pacemakers, and subcutaneous implantable cardioverter defibrillators (S-ICD), are mostly used in the management of patients who are at high risk for surgery and/or developing infections. Several mechanisms render most of these devices resistant to infection, including avoiding long transvenous access and novel manufacturing material. Since subjects who use these devices already endure several comorbid conditions, uncommon cases of device-associated infection could result in serious complications and increased mortality. In this review, we aim to summarize the current state of evidence on the incidence, clinical presentation, management, and prognosis of new cardiac devices' associated infection.
新型心脏设备，包括二尖瓣夹合系统、封堵器、无导线起搏器和皮下植入式心律转复除颤器（S-ICD），主要用于治疗手术风险高和/或有感染风险的患者。这些设备大多通过多种机制来抵抗感染，包括避免长时间经静脉通路以及使用新型制造材料。由于使用这些设备的患者已经患有多种合并症，罕见的与设备相关的感染病例可能会导致严重并发症并增加死亡率。在本综述中，我们旨在总结有关新型心脏设备相关感染的发生率、临床表现、管理和预后的现有证据状况。
